Suven Secures Four New Product Patents | CORPORATE ETHOS

Suven Secures Four New Product Patents

By: | July 4, 2018
suven life sciences

Jul 4: Hyderabad-based biopharma firm Suven Life Sciences Ltd on Wednesday announced that the company has been granted four product patents from India (297139), Singapore (11201604849Y), South Korea (10-1865868) and Israel (253848) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2031, 2034, 2034 and 2036 respectively.

According to the company, the granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Shares of the company were trading at Rs 213.70, up 2.47% from the previous closing of Rs 208.55, on BSE at 12.10 pm today.